MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good morning, and welcome to the MannKind Corporation Second ...

In summary, MannKind Corporation’s earnings call reflects a positive outlook, driven by strong financial performance and strategic advancements in its product pipeline. Despite challenges in certain ...

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...

MannKind Corporation (NASDAQ: MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

MannKind Corporation ( MNKD) has disclosed a new risk, in the Capital Markets category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

The biopharmaceutical company posted adjusted earnings of $0.05 per share for the second quarter, matching analyst estimates. However, revenue came in at $76.53 million, below the consensus estimate ...

MannKind Corporation (NASDAQ:MNKD) is one of the best biotech penny stocks to buy right now.